# PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma

**Authors:** Xiaoxia Xu, Xiangxiang Ding, Xiao Jin, Yunfei Shi, Zhi Yang, Nan Li

PMC · DOI: 10.3389/fimmu.2025.1607177 · Frontiers in Immunology · 2025-07-16

## TL;DR

A new model using PET/CT scans and blood markers improves early survival predictions for patients with a rare type of T-cell lymphoma.

## Contribution

A novel prognostic model combining PET/CT parameters and clinical indicators for early survival prediction in AITL.

## Key findings

- SUVmax, β2MG, platelet, and albumin were identified as independent risk factors for survival.
- The model achieved a C-index of 0.78 and high AUC values for 6-month and 1-year survival prediction.
- The model outperformed existing systems like PIAI, IPI, and PIT in predictive accuracy.

## Abstract

To develop and validate a new prognostic model using baseline PET parameters and clinical indicators for predicting early overall survival (OS) in Angioimmunoblastic T-cell lymphoma (AITL) patients.

We conducted a retrospective cohort study from December 2009 to December 2023 (n=124) at a single center. The model’s predictors included baseline clinical characteristics, pathological indicators, laboratory metrics, and PET/CT parameters. Independent prognostic factors were identified using Cox regression and presented as nomograms. The C-index assessed predictive accuracy, while calibration plots and decision curve analysis evaluated prediction accuracy and discrimination ability. The model’s accuracy was compared with existing prognostic systems using C-index, NRI, ROC, and Kaplan-Meier survival curves.

SUVmax, β2MG, platelet, and albumin were identified as independent risk factors. The C-index for OS was 0.78 (95% CI: 0.70-0.85); for 1000 bootstrap samples, it was 0.76 (95% CI: 0.61-0.93). Calibration curves showed excellent agreement between predictions and actual observations. The AUC for 6-month and 1-year OS were 0.91(95% CI: 0.82-1.00) and 0.85 (95% CI: 0.77–0.94), respectively. The model outperformed PIAI, IPI, and PIT in predictive capacity.

The new prediction model reliably estimates outcomes for AITL patients, demonstrating high discrimination and calibration.

## Linked entities

- **Diseases:** Angioimmunoblastic T-cell lymphoma (MONDO:0004977), AITL (MONDO:0004977)

## Full-text entities

- **Genes:** HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** adult T-cell leukemia/lymphoma (MESH:D015459), death (MESH:D003643), IPI (MESH:D000082122), diffuse large B-cell lymphoma (MESH:D016403), follicular lymphoma (MESH:D008224), non-Hodgkin's lymphoma (MESH:D008228), intestinal lymphomas (MESH:D008223), peripheral T-cell lymphoma (MESH:D016411), lesion (MESH:D009059), Cancer (MESH:D009369), stages III to IV disease (MESH:D007676), infections (MESH:D007239), AITL (MESH:D016399), diffuse mantle cell lymphoma (MESH:D020522), Ann Arbor stage (MESH:D062706), OS (MESH:D011475), Hodgkin lymphoma (MESH:D006689)
- **Chemicals:** blood glucose (MESH:D001786), cyclophosphamide, doxorubicin, vincristine, and prednisone (-), 18F-FDG (MESH:D019788)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12307193/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12307193/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12307193/full.md

---
Source: https://tomesphere.com/paper/PMC12307193